ORIC — Oric Pharmaceuticals Inc

Oric Pharmaceuticals Inc (ORIC) is a biotechnology company listed on NASDAQ. It is led by Jacob M. Chacko M.B.A., M.D., based in 240 E. Grand Ave, South San Francisco, CA, United States, 94080, with about 104 employees. ORIC Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of therapies to counter the resistance mechanisms in cancers in the United States. Its clinical stage product candidates include enozertinib formerly known as ORIC-114, a brain penetrant orally bioavailable irreversible inhibitor, currently under Phase 1b study, that selectively target epidermal growth factor receptor (EGFR) exon 20 and human epidermal growth factor receptor 2 exon 20 with high potency towards exon 20 insertion mutations; and rinzimetostat formerly known as ORIC-944, an allosteric inhibitor of the polycomb repressive complex 2 for prostate cancer, currently under Phase 1b study. It has a clinical trial collaboration and supply agreement with Bayer to evaluate ORIC-944 in combination with Nubeqa AR inhibitor; and a clinical trial collaboration and supply agreement with Johnson & Johnson to evaluate ORIC 944 in combination with Erleada AR inhibitor. The company was incorporated in 2014 and is headquartered in South San Francisco, California.

Net income was -$32.6M. ORIC currently screens at market cap $893.4M.

Use this ORIC page for company research — sector, financials, and the latest filing takeaway — not a live tape. The session quote (last, range, volume) lives on the ORIC quote page. Cached 10-K, 10-Q, 8-K, and Form 4 exhibits are on the ORIC SEC filings page. Lician reads the product cache first so this HTML stays unique to Oric Pharmaceuticals Inc even when a live quote feed is slow.